• 1.中國醫(yī)學科學院中國協和醫(yī)科大學北京協和醫(yī)院普通外科（北京100730）;;
  • 2.中國醫(yī)學科學院中國協和醫(yī)科大學北京協和醫(yī)院消化內科;

目的檢測生長抑素Ⅱ型受體（SSTR2） mRNA在大腸癌標本中的表達，并探討其表達與腫瘤臨床及病理特點的關系。方法對36例大腸癌患者于術后立即取其手術切除之正常大腸粘膜（距腫瘤10 cm以上）、癌旁粘膜（距腫瘤2 cm以內）、腫瘤組織及腸系膜淋巴結標本共135份，采用RT-PCR法檢測其SSTR2 mRNA的表達，并比較不同組織之間SSTR2 mRNA表達陽性率的差別。結果正常大腸粘膜、癌旁粘膜、腫瘤組織以及無腫瘤轉移的腸系膜淋巴結和有腫瘤轉移的腸系膜淋巴結的SSTR2 mRNA表達陽性率分別為67.6%（23/34）、75.0%(24/32)、91.4%(32/35)、93.8%(15/16)和81.8%(9/11)。腫瘤組織中SSTR2 mRNA的表達陽性率較正常大腸粘膜明顯增高（χ2=6.37，P＜0.05），但其表達陽性率在不同性別、血清CEA水平、腫瘤大小、部位、組織學分級以及不同腫瘤分期的患者中差異并無顯著性意義（P＞0.05）。結論SSTR2 mRNA的表達在大腸癌組織中明顯增高，其表達與否和腫瘤的組織學分級及臨床病理分期無關。

引用本文： 李小毅,唐偉松,陳原稼,陳元方. 生長抑素Ⅱ型受體在大腸癌中的表達. 中國普外基礎與臨床雜志, 2004, 11(4): 347-350. doi: 復制

1. 陳元方， 張萬岱. 胃腸肽類激素，生長因子與消化系統(tǒng)非內分泌性惡性腫瘤. 見： 陳元方主編. 胃腸肽類激素基礎與臨床 [M]. 第1版. 北京： 北京醫(yī)科大學中國協和醫(yī)科大學聯合出版社， 1997∶752～760.
2. Pages P, Benali N, SaintLaurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP1 [Ｊ]. J Biol Chem, 1999; 274(21)∶15186.
3. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201995 in treatment of human endocrine tumors [Ｊ]. J Clin Invest, 1994; 93(3)∶1321.
4. NakajimaIijima S, Hamada H, Reddy P, et al. Molecular structure of the human cytoplasmic betaactin gene: interspecies homology of sequences in the introns [Ｊ]. Proc Natl Acad Sci USA, 1985; 82(18)∶6133.
5. Buscail L, SaintLaurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer [Ｊ]. Cancer Res, 1996; 56(8)∶1823.
6. Laws SA, Gough AC, Evans AA, et al. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae [Ｊ]. Br J Cancer, 1997; 75(3)∶360.
7. Vuaroqueaux V, Dutour A, Briard N, et al. No loss of sst receptors gene expression in advanced stages of colorectal cancer [Ｊ]. Eur J Endocrinol, 1999; 140(4)∶362.
8. Vuaroqueaux V, Dutour A, Bourhim N, et al. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma [Ｊ]. J Mol Endocrinol, 2000; 24(3)∶397.
9. Reubi JC, Waser B, Schmassmann A, et al. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: where are they really located? [Ｊ]. Int J Cancer, 1999; 81(3)∶376.
10. Stolz B, Weckbecker G, SmithJones PM, et al. The somatostatin receptortargeted radiotherapeutic 90YDOTADPhe1, Tyr3 octreotide (90YSMT 487) eradicates experimental rat pancreatic CA 20948 tumours [Ｊ]. Eur J Nucl Med, 1998; 25(7)∶668.
11. Plonowski A, Schally AV, Nagy A, et al. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN238 [Ｊ]. Cancer Res, 2000; 60(11)∶2996.
  1. 1. 陳元方， 張萬岱. 胃腸肽類激素，生長因子與消化系統(tǒng)非內分泌性惡性腫瘤. 見： 陳元方主編. 胃腸肽類激素基礎與臨床 [M]. 第1版. 北京： 北京醫(yī)科大學中國協和醫(yī)科大學聯合出版社， 1997∶752～760.
  2. 2. Pages P, Benali N, SaintLaurent N, et al. sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP1 [Ｊ]. J Biol Chem, 1999; 274(21)∶15186.
  3. 3. Kubota A, Yamada Y, Kagimoto S, et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201995 in treatment of human endocrine tumors [Ｊ]. J Clin Invest, 1994; 93(3)∶1321.
  4. 4. NakajimaIijima S, Hamada H, Reddy P, et al. Molecular structure of the human cytoplasmic betaactin gene: interspecies homology of sequences in the introns [Ｊ]. Proc Natl Acad Sci USA, 1985; 82(18)∶6133.
  5. 5. Buscail L, SaintLaurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer [Ｊ]. Cancer Res, 1996; 56(8)∶1823.
  6. 6. Laws SA, Gough AC, Evans AA, et al. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae [Ｊ]. Br J Cancer, 1997; 75(3)∶360.
  7. 7. Vuaroqueaux V, Dutour A, Briard N, et al. No loss of sst receptors gene expression in advanced stages of colorectal cancer [Ｊ]. Eur J Endocrinol, 1999; 140(4)∶362.
  8. 8. Vuaroqueaux V, Dutour A, Bourhim N, et al. Increased expression of the mRNA encoding the somatostatin receptor subtype five in human colorectal adenocarcinoma [Ｊ]. J Mol Endocrinol, 2000; 24(3)∶397.
  9. 9. Reubi JC, Waser B, Schmassmann A, et al. Receptor autoradiographic evaluation of cholecystokinin, neurotensin, somatostatin and vasoactive intestinal peptide receptors in gastrointestinal adenocarcinoma samples: where are they really located? [Ｊ]. Int J Cancer, 1999; 81(3)∶376.
  10. 10. Stolz B, Weckbecker G, SmithJones PM, et al. The somatostatin receptortargeted radiotherapeutic 90YDOTADPhe1, Tyr3 octreotide (90YSMT 487) eradicates experimental rat pancreatic CA 20948 tumours [Ｊ]. Eur J Nucl Med, 1998; 25(7)∶668.
  11. 11. Plonowski A, Schally AV, Nagy A, et al. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin AN238 [Ｊ]. Cancer Res, 2000; 60(11)∶2996.